Amphastar Pharmaceuticals Management

Management criteria checks 3/4

Amphastar Pharmaceuticals' CEO is Jack Zhang, appointed in Jan 1996, has a tenure of 28.75 years. total yearly compensation is $7.72M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 5.01% of the company’s shares, worth €111.56M. The average tenure of the management team and the board of directors is 10.9 years and 5.3 years respectively.

Key information

Jack Zhang

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage	11.6%
CEO tenure	28.8yrs
CEO ownership	5.0%
Management average tenure	10.9yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jack Zhang's remuneration changed compared to Amphastar Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$167m
Mar 31 2024	n/a	n/a	US$155m
Dec 31 2023	US$8m	US$898k	US$138m
Sep 30 2023	n/a	n/a	US$135m
Jun 30 2023	n/a	n/a	US$102m
Mar 31 2023	n/a	n/a	US$93m
Dec 31 2022	US$7m	US$1m	US$91m
Sep 30 2022	n/a	n/a	US$77m
Jun 30 2022	n/a	n/a	US$91m
Mar 31 2022	n/a	n/a	US$81m
Dec 31 2021	US$7m	US$898k	US$62m
Sep 30 2021	n/a	n/a	US$36m
Jun 30 2021	n/a	n/a	US$10m
Mar 31 2021	n/a	n/a	US$2m
Dec 31 2020	US$6m	US$898k	US$1m
Sep 30 2020	n/a	n/a	US$7m
Jun 30 2020	n/a	n/a	US$4m
Mar 31 2020	n/a	n/a	US$52m
Dec 31 2019	US$6m	US$898k	US$49m
Sep 30 2019	n/a	n/a	US$52m
Jun 30 2019	n/a	n/a	US$53m
Mar 31 2019	n/a	n/a	US$2m
Dec 31 2018	US$6m	US$1m	-US$6m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$6m	US$880k	US$4m

Compensation vs Market: Jack's total compensation ($USD7.72M) is above average for companies of similar size in the German market ($USD2.59M).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.

CEO

Jack Zhang (77 yo)

28.8yrs

Tenure

US$7,722,768

Compensation

Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ziping Luo	Chairman of the Board	28.8yrs	US$3.77m	2.36% € 52.5m
Yongfeng Zhang	Co-founder	28.8yrs	US$7.72m	5.01% € 111.6m
William Peters	CFO, Executive VP of Finance	10.5yrs	US$2.89m	0.075% € 1.7m
Jacob Liawatidewi	Executive VP of Sales	11.3yrs	US$1.78m	0.096% € 2.1m
Rong Zhou	Senior EVP of Production & EVP of Scientific Affairs	9.3yrs	US$2.03m	0.38% € 8.6m
Dan Dischner	Senior Vice President of Human Resources & Corporate Communication	2.2yrs	no data	no data
Tony Marrs	Executive VP of Regulatory Affairs & Clinical Operations	no data	no data	no data

10.9yrs

Average Tenure

65yo

Average Age

Experienced Management: 29A's management team is seasoned and experienced (10.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ziping Luo	Chairman of the Board	28.8yrs	US$3.77m	2.36% € 52.5m
Yongfeng Zhang	Co-founder	28.8yrs	US$7.72m	5.01% € 111.6m
William Peters	CFO, Executive VP of Finance	2.2yrs	US$2.89m	0.075% € 1.7m
Jacob Liawatidewi	Executive VP of Sales	2.2yrs	US$1.78m	0.096% € 2.1m
Richard Prins	Lead Independent Director	22.7yrs	US$362.00k	0.063% € 1.4m
Gayle Deflin	Independent Director	3.3yrs	US$330.00k	0% € 0
Chen Yang	Member of Scientific Advisory Board	no data	no data	no data
Paul White	Member of Scientific Advisory Board	no data	no data	no data
Gordon Treweek	Member of Scientific Advisory Board	no data	no data	no data
Herschel Rabitz	Member of Scientific Advisory Board	no data	no data	no data
Richard Porter	Member of Scientific Advisory Board	no data	no data	no data
Diane Gerst	Independent Director	5.3yrs	US$314.70k	0.026% € 587.6k

5.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 29A's board of directors are considered experienced (5.3 years average tenure).

Amphastar Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Insider recently sold €543k worth of stock

Lead Independent Director recently sold €245k worth of stock

Insider recently sold €668k worth of stock

Insider recently sold €291k worth of stock

Recent updates

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.54 in 2Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Insider recently sold €543k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: US$2.85 (vs US$1.88 in FY 2022)

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Investor sentiment deteriorates as stock falls 17%

Lead Independent Director recently sold €245k worth of stock

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insider recently sold €668k worth of stock

Investor sentiment deteriorates as stock falls 18%

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.54 (vs US$0.35 in 2Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Insider recently sold €291k worth of stock

First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023

Investor sentiment deteriorates as stock falls 17%

Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021)

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.61 in 3Q 2021)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$0.35 (vs US$0.16 in 2Q 2021)

Amphastar Pharmaceuticals, Inc. Announces Executive Changes

Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Investor sentiment improved over the past week

Chairman of the Board recently sold €3.5m worth of stock

First quarter 2022 earnings released: EPS: US$0.50 (vs US$0.11 in 1Q 2021)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$0.61 (vs US$0.083 in 3Q 2020)

Independent Director David Maris has left the company

Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million.

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.004 loss in 2Q 2020)

Insider recently sold €76k worth of stock

Insider recently sold €73k worth of stock

First quarter 2021 earnings released: EPS US$0.11 (vs US$0.085 in 1Q 2020)

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Morphine Sulfate Injection

Full year 2020 earnings released: EPS US$0.03 (vs US$1.04 in FY 2019)

Amphastar Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021

New 90-day low: €14.50

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

New 90-day low: €15.00

Revenue misses expectations

Third quarter 2020 earnings released: EPS US$0.083

Amphastar Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 06, 2020

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

New 90-day low: €15.80

New 90-day low - €16.50

Earnings released

Amphastar Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

CEO Compensation Analysis

CEO

Tenure